Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?
Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.
Novo Nordisk’s Awiqli approval could change how basal insulin is used in type 2 diabetes
Novo Nordisk’s Awiqli wins FDA approval as the first once-weekly basal insulin. Read what this could change for type 2 diabetes care.
What the Hims & Hers Health, Inc. and Novo Nordisk collaboration reveals about the future of obesity drug commercialization
Explore how Hims & Hers and Novo Nordisk are expanding GLP-1 access and what it means for obesity care, pricing, and regulation.
C2N Diagnostics advances PrecivityTauDx programme as tangle biomarker gains Phase 3 evidence
C2N’s eMTBR-tau243 plasma assay shows independent prognostic value in Phase 3 Evoke data. What this means for Alzheimer’s patient selection. Read the analysis.
Novo Nordisk–Prothena coramitug program reaches key Phase 3 milestone in ATTR cardiomyopathy
Prothena earns a $50M milestone as Novo Nordisk advances coramitug in Phase 3 for ATTR cardiomyopathy. Discover what this means for amyloid therapies.
Amazon adds oral Wegovy to pharmacy platform: Will this reshape obesity care logistics?
Amazon Pharmacy now delivers oral Wegovy with insurance and cash-pay options. Find out how this reshapes GLP-1 access and obesity care.
Can Novo Nordisk’s semaglutide 7.2 mg set a new standard in obesity treatment?
Novo Nordisk’s semaglutide 7.2 mg achieves 20.7% weight loss. Find out what this EU regulatory step means for obesity treatment and patient outcomes in 2026.
Novo Nordisk finalizes $5.2bn Akero deal to expand in advanced MASH care
Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.
Can higher-dose Wegovy reshape the obesity treatment curve for Novo Nordisk?
Novo Nordisk’s semaglutide 7.2 mg dose aims to raise Wegovy’s weight loss impact. Learn how this could shift obesity treatment and reshape clinical norms.